Zydus Cadila receives final approval from the USFDA to market Midodrine Hydrochloride Tablets

Press Release Press Release Press Release Press Release Press Release Press Release Press Release Press Re²lease Cadila Healthcare Limited Regd. Office : ‘Zydus Corporate Park’, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, India. Phone : +91-079-71800000, +91-079-48040000 www.zyduscadila.com CIN : L24230GJ1995PLC025878 For further information please contact : The Corporate Communications Department Zydus Cadila receives final approval from the USFDA to market Midodrine Hydrochloride Tablets Ahmedabad, September 3, 2020 Zydus Cadila received final approval from the USFDA to market Midodrine Hydrochloride Tablets (US RLD- ProAmatine Tablets) in the strengths of 2.5 mg, 5 mg, and 10 mg. The drug is used for certain patients who have symptoms of low blood pressure when standing. This condition is also known as orthostatic hypotension. The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad. The group now has 298 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. ***

The release as fetched from its publisher. zyduslife.com ↗